NS Pharma has shared an update that their parent company, Nippon Shinyaku, has entered a partnership for exclusive commercialization and distribution of CAP-1002 for the treatment of Duchenne muscular dystrophy in the U.S.
Read their community letter below or click here to view their full press release.
January 25, 2022
Dear Duchenne Community,
Greetings from NS Pharma, Inc.
We are excited to share the news that our parent company, Nippon Shinyaku, has entered into an exclusive partnership with Capricor Therapeutics for the commercialization and distribution of a new, investigational regenerative medicine therapy CAP-1002. You can read the press release that Nippon Shinyaku issued here.
CAP-1002 joins a robust pipeline of Duchenne products from our parent company. We believe that it has the potential to be a treatment for Duchenne patients, regardless of the type of genetic deletion that caused their disease. This therapy is expected to be exon deletion agnostic.
We were encouraged by the Phase 2 results reported last year highlighting the impact of CAP-1002 on skeletal muscle and heart function. Furthermore, the investigational medicine CAP-1002 represents a potential treatment that is first-in-class and ready to begin a Phase 3 clinical trial to support FDA approval in the US. NS Pharma and Capricor will keep the Duchenne community informed about key developments regarding a Phase 3 trial of CAP-1002.
NS Pharma is committed to finding and developing effective and safe treatments for Duchenne patients and their families. We continue to focus our R&D expertise on Duchenne treatments including additional exon skipping therapies – and we are looking forward to sharing more R&D developments in the coming year.
Thank you,
Tsugio Tanaka
President,
NS Pharma, Inc.
